Radius Appoints Ed Cinca as Chief Commercial Officer

Cambridge, Mass., October 27, 2022 – Radius Health, Inc. (“Radius” or the “Company”), Radius Health (“Radius”), a specialty biopharmaceutical company dedicated to bone health and expanding access for patients, today announced the appointment of Ed Cinca to the role of Chief Commercial Officer, reporting to Radius’s Chief Executive Officer, Scott Briggs.

As the Chief Commercial Officer, Ed’s role will be to lead the commercial functions of Radius and its portfolio moving forward. Ed’s immediate focus will be on Tymlos, (abaloparatide) injection and the development of an integrated strategic approach across all commercial channels, and as the portfolio of products also expand.

“Osteoporosis affects over ten million Americans with another 44 million having low bone density which present greater risk for bone breakage.” said Radius’s CEO, Scott Briggs. “Radius is dedicated to bone health around the world and having Ed join my executive team increases our ability to help accelerate our success in taking on this endeavor.”

“Radius is an industry leader in the bone health and I’m looking forward to applying my commercial experience in brand excellence to help Radius achieve its potential at such an exciting time in the company’s evolution.” said Ed Cinca. “Osteoporosis-related bone breaks cost patients, their families, and the healthcare system $20 billion annually. Helping to address this silent crisis is meaningful to me and my family and I am eager to make a difference.”

Prior to joining Radius, Ed most recently served as an Executive Team Member to Currax Pharmaceuticals where he was responsible for the commercialization of their obesity portfolio, leveraging his years of expertise from his days as Head of Cardiometabolic Portfolio at Novo Nordisk, Inc. (NNI) where he led the launches of Ozempic, Rybelsus and Wegovy. Ed earned an MBA in Marketing and Finance from Fordham University and a Bachelor of Science in Finance from Lehigh University. He is also a board member of the New York/New Jersey American Diabetes Association and member of Steps Together, an organization that supports families impacted by medical crises.

References

1. National Osteoporosis Foundation, Osteoporosis Fast Facts, www.nof.org
2. About Radius
   Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis and the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group.

Media Contact:
Ethan Holdaway
Email: [email protected]
Phone: (617) 583-2017